<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058742</url>
  </required_header>
  <id_info>
    <org_study_id>VNS</org_study_id>
    <nct_id>NCT05058742</nct_id>
  </id_info>
  <brief_title>Non-invasive Nervus Vagus Stimulation in Patients With COVID-19 and ARDS</brief_title>
  <official_title>Noninvasive Vagal Nerve Stimulation in Patients With COVID-19 and ARDS for the Reduction of Respiratory, Hemodynamic and Neuropsychiatric Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vienna Hospital Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Hospital Association</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critical ill COVID-19 patients often develop respiratory, hemodynamic and neuropsychiatric&#xD;
      complications. An imbalance of sympatho-parasympathetic nervous system is discussed as one of&#xD;
      the reasons. The nervus vagus is essential for controlling the sympatho-parasympathetic&#xD;
      nervous system and the inflammatory processes.&#xD;
&#xD;
      Aim of this study is to evaluate whether Nervus vagus stimulation decreases the rate of&#xD;
      complications (e.g. need of mechanical ventilation, hospital stay, mortality) in critical ill&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      Critical ill COVID-19 patients often develop respiratory, hemodynamic and neuropsychiatric&#xD;
      complications. An imbalance of sympatho-parasympathetic nervous system is discussed as one of&#xD;
      the reasons. The nervus vagus is essential for controlling the sympatho-parasympathetic&#xD;
      nervous system and the inflammatory processes. A method to stimulate the nervus vagus, is the&#xD;
      non-invasive Nervus Vagus Stimulation with AuriStim.&#xD;
&#xD;
      Aims:&#xD;
&#xD;
      Aim of this study is to evaluate whether Nervus vagus stimulation decreases the rate of&#xD;
      complications (e.g. need of mechanical ventilation, hospital stay, mortality) in critical ill&#xD;
      patients.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      All patients admitted to ICU at Klinik Favoriten with COVID-19 and moderate to severe ARDS&#xD;
      are asked to partcipate. After written consent, a randomisation in Treatment-group (Vagal&#xD;
      Nervus Stimulation 4 times a day for each 3 hours until transfer to nomal ward or death) or&#xD;
      Non-Treatment-Group is done. In case of stimulation, side effects or intolerance are&#xD;
      documented. After discharge or death of the patient, outcomeparameters are evaluated (need of&#xD;
      mechanical ventilation, hospital stay, mortality, etc.) and compared between patients of&#xD;
      Treatment-Group and Non-Treatment-Group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nervus vagus stimulation decreases the rate of complications (e.g. need of mechanical ventilation, hospital stay, mortality)</measure>
    <time_frame>3 months after admission to ICU</time_frame>
    <description>retrospective analysis after discharge or death or participant</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <condition>ARDS</condition>
  <condition>Cytokine Storm</condition>
  <arm_group>
    <arm_group_label>Nervus vagus stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-invasive Nervus vagus stimulation called AuriStim Intermittent stimluation cycle of three hours of activity and three hours of rest, equating to four cycles of three hours of Stimulation in 24 hours) is performed. The stimulation is performed until the patient's condition is better and he or she isdischarged from OCU or transferred to normal ward or dies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>There is no Nervus vagus stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AuriStim</intervention_name>
    <description>Auricular vagal nerve Stimulator, which Targets the auricular branches of the vagal nerve</description>
    <arm_group_label>Nervus vagus stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  positive SARS-CoV-2 RT-PCR&#xD;
&#xD;
          -  Acute respiratory failure requiring non-invasive respiratory support (NIV or high flow&#xD;
             Oxygen)&#xD;
&#xD;
          -  PaO2/FiO2 &lt;200&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy (to be excluded using Serum betaHCG in women of childbearing age)&#xD;
&#xD;
          -  Signs of infection, eczema or Psoriasis at the application site&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Implanted cardiac Pacemaker, deficrillator or other active implanted electrical&#xD;
             devices&#xD;
&#xD;
          -  Patient unable to consent&#xD;
&#xD;
          -  Heart rate &lt;60/min&#xD;
&#xD;
          -  Known vagal hypersensitivity&#xD;
&#xD;
          -  History of hemophilia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Zoufaly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik Favoriten</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reinhard Kitzberger, MD</last_name>
    <phone>+431601910</phone>
    <email>reinhard.kitzberger@gesundheitsverbund.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamara Seitz, MD</last_name>
    <phone>+4316019172412</phone>
    <email>tamara.seitz@gesundheitsverbund.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik Favoriten</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Kitzberger, MD</last_name>
      <phone>+4301601910</phone>
      <email>reinhard.kitzberger@gesundheitsverbund.at</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Seitz, MD</last_name>
      <phone>+43016019172412</phone>
      <email>tamara.seitz@gesundheitsverbund.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nervus vagus stimulation</keyword>
  <keyword>COVID-19</keyword>
  <keyword>ARDS</keyword>
  <keyword>hyperinflammation</keyword>
  <keyword>cytokine storm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

